Approval · Notice of Compliance 19992 · 2017
CONSTELLA: Notice of Compliance 19992
Issued November 2, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19992
- Date
- November 2, 2017
- Company
- Forest Laboratories Canada IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength - 72 mcg
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONSTELLA | 02469510 | Marketed |
| CONSTELLA | Not yet assigned | — |
Medicinal ingredients
- LINACLOTIDE 72 MCG per CAP
- LINACLOTIDE 145 MCG per CAP
- LINACLOTIDE 290 MCG per CAP